Dana-Farber Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dana-Farber Cancer Institute sits in the top decile of US sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count).
Dana-Farber Cancer Institute: 781 sponsored US clinical trials, 112 recruiting.
Dana-Farber Cancer Institute sponsors 781 registered US clinical trials on ClinicalTrials.gov, 112 of them currently recruiting, and 449 completed. 15 of these trials are in Phase 3-4 (later-stage) and 492 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 53 trials.
Top-decile sponsor footprint
Dana-Farber Cancer Institute ranks in the top decile of sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
449 of 537 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
781 total, page 12 of 16
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
NCT00942682
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
NCT00903968
Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
NCT00928018
Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
NCT00782626
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
NCT00910000
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
NCT00903162
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
NCT00834093
Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies
NCT00973440
Multiple Risk Behavior Intervention in Health Care Settings
NCT01415492
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
NCT00790010
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
NCT00856050
Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin
NCT00831571
Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies
NCT00856180
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
NCT00788775
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
NCT00808639
A Pilot Study of Acupuncture Treatment for Dysphagia
NCT00797732
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
NCT00815919
Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation
NCT00809250
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
NCT00804336
Computerized Assessment for Patients With Cancer
NCT00852852
Collection and Banking of Leukemia Cells MDS/AML
NCT00809367
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
NCT00776594
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
NCT00768144
Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation
NCT00658411
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
NCT00684411
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
NCT00658697
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
NCT00576680
Lung Cancer Symptom Assessment and Management Intervention
NCT00852462
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
NCT00611858
Observational Study of Iron Overload in Stem Cell Transplantation
NCT00954720
A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors
NCT00633958
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
NCT00630344
Hypertension in Breast Cancer Patients Receiving Bevacizumab
NCT00674011
Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies
NCT00675831
Simvastatin in Waldenstrom's Macroglobulinemia
NCT00575965
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
NCT00542451
Vitamin D for Chemoprevention
NCT00585637
Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation
NCT00548717
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
NCT00543114
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
NCT00520013
Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma
NCT00512889
Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
NCT00529035
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
NCT00577382
Campath in Chronic GVHD
NCT00495755
Rapamycin in Relapsed Acute Lymphoblastic Leukemia
NCT00874562
ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer
NCT00496665
Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma
NCT00487305
Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials
NCT00487513
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
NCT00545792
Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
NCT00483262
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 181 |
| Phase 2 | 311 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Dana-Farber Cancer Institute pipeline
112 recruiting of 781 indexed (14% open); 449 completed (57%).
Phase mix: 15 late (III/IV) vs 492 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (53 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dana-Farber Cancer Institute: open-pipeline peers nationwide
Peers matched on 781 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 781 trials (± recruiting share)
- University of California, San Diego · 775 trials · 18% recruiting
- University of Chicago · 796 trials · 20% recruiting
- Medical University of South Carolina · 755 trials · 19% recruiting
- University of Utah · 818 trials · 17% recruiting
Sponsors near 14% open enrollment (± trial volume)
- The Cleveland Clinic · 14% recruiting · 688 trials
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
Related
What to do with this Dana-Farber Cancer Institute page
781 registered trials is a research-attention snapshot, not an endorsement of Dana-Farber Cancer Institute or any single study.
- 112 of Dana-Farber Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Dana-Farber Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dana-Farber Cancer Institute pipeline card: 781 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.